Pfizer to Sell 7.7% Stake in Haleon via Secondary Offering

MT Newswires47minutes ago

Express News | Pfizer plans to further reduce its shareholding in Helion by approximately 7.7%.

Breakings12:14

Pfizer further reduced its shareholding in Haleon, cashing out 2.6 billion British Pound.

On January 15, at Glonghui, Pfizer, a USA pharmaceutical company, is again selling shares of the United Kingdom consumer health company Haleon, with estimated cash proceeds of 2.6 billion British Pound. According to the announcement, Pfizer will place 7.7% of Haleon's shares through agents on the London Exchange. Based on Haleon's closing price on Tuesday and the sales documents, the transaction value is expected to be 2.6 billion British Pound. Sources indicate that investors have shown strong interest in Haleon's placement, with subscription amounts exceeding the placement size. Last year, Pfizer also placed Haleon shares, cashing out 2.4 billion British Pound.

Gelonghui Finance09:07

Bernstein Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $32

Futu News07:31 · Ratings

Bernstein Reaffirms Their Hold Rating on Pfizer (PFE)

TipRanks07:26 · Ratings

Pfizer Appeals Denial of $75 Million Claim in SEC Case Against Cohen Hedge Fund

Yahoo Finance06:34